Webinar: Presentation of technology offers in the field of biomarker development

Organized by the working group “technology transfer” of BIO Deutschland

The working group “technology transfer” of BIO Deutschland is pleased to offer a new webinar series. The first offering will present several biomarker developments by academic institutions and will take place:

July 1 2014, 3:30 pm to 4:30 pm CEST

Please register for the webinar “Presentation of technology offers in the field of biomarker development”  on Jul 1, 2014 3:30 PM CEST at: https://attendee.gotowebinar.com/register/8992012059554553090

Each presentation will take approximately 10 minutes with time for questions (instant messaging).

If you have questions regarding this upcoming webinar please contact:

Dr. Claudia Englbrecht, englbrecht@biodeutschland.org, Tel.: +49 30 72625-132

Program

Invention “Mutation Detect”

Dr. Frank Breitenbücher, West German Cancer Center, University Hospital Essen

Platform technology for highly sensitive detection of somatic gene modifications from cancer patients. The technology might be useful for rapid stratification of patients for mutation-directed personalized pharmacotherapy. Suitable to use DNA from biopsies, DNA from circulating tumor cells (CTC) and free DNA from plasma/serum samples, sequential analyses are possible and may facilitate "online monitoring" of treatment response on a genomic level. Contact: Provendis www.provendis.info

Invention: Biomarker for DNA-methylation

Prof. Dr. Barbara Burwinkel & Dr. Rongxi Yang, Heidelberg University Hospital

Methylation and expression of four genes from peripheral blood as a panel for breast cancer early detection and risk evaluation. HYAL2 methylation and expression in peripheral blood as bio-marker for breast cancer and ovarian cancer early detection. Contact: Technologiepark Heidelberg www.technologiepark-heidelberg.de/ & technology transfer heidelberg GmbH www.klinikum.uni-heidelberg.de/technologietransfer

Invention: Fraunhofer in-vitro diagnostic platform

Dr. rer. nat. Soeren Schumacher, M.B.A., Fraunhofer Institute for Biomedical Engineering IBMT

Under the name of „Fraunhofer in-vitro diagnostic platform“ (ivD-Platform), seven Fraunhofer Institutes developed a diagnostic system, which enables the measurement of multiple diagnostic parameters directly at the point-of-care. The system consists of a credit-card sized cartridge and a base-unit. The physician or medically trained personnel takes a sample, for example a drop of blood preferably from the finger pulp, and insert this into the cartridge. The cartridge already holds all necessary biochemical reagents, a microarray slide and also a proprietary pumping system enabling an automated processing after insertion of the cartridge into the base-unit. After a time of about fifteen minutes, the results of the diagnostic analysis appear on a display and the physician can directly undertake therapeutic action. The functionality of the Fraunhofer ivD-platform was already demonstrated. Further assays and assay types can easily be transferred onto the platform. Therefore exclusive partnering possibilities can be offered. Contact: Berlin Partner für Wirtschaft und Technologie GmbH www.berlin-partner.de

Invention: Protein biomarker set for personalized treatment of breast cancer

Johanna Sonntag, Ulrike Korf, Christian Bender, Stefan Wiemann, German Cancer Research Institute (Deutsches Krebsforschungszentrum, DKFZ)

The histologic grade of luminal breast cancer is currently determined by semi-quantitative methods describing morphologic features related to the differentiation states of the tumor specimen. In order to make a clear-cut and consistent classification of luminal breast cancer as either “grade 1” (= low risk) or “grade 3” (= high risk) tumors, DKFZ researchers have developed a cost-effective and simple to apply 3-protein marker set.  Contact: Dr. Ruth Herzog (r.herzog@dkfz.de)